Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial

Abstract In this phase I study, we test a pooled synthetic long peptide vaccine targeting the six KRAS mutations (G12V, G12A, G12R, G12C, G12D, G13D) with ipilimumab and nivolumab in resected pancreatic adenocarcinoma. Co-primary endpoints include safety and maximal percent change of IFNγ-producing...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Amanda L. Huff, S. Daniel Haldar, Alexander A. Girgis, Hejia Henry Wang, Ludmila Danilova, Thatcher Heumann, Maureen Berg, Yuxuan Wang, Lalitya Andaloori, Alexei Hernandez, Gabriella Longway, Benjamin Barrett, Zirui Zhu, Emily Davis-Marcisak, Christopher Thoburn, James Leatherman, Sarah Mitchell, Jae W. Lee, Daniel H. Shu, Maximillian F. Konig, Brian J. Mog, Janelle Montagne, Erin M. Coyne, Katherine Bever, Marina Baretti, Mark Yarchoan, Robert A. Anders, Luciane T. Kagohara, Daniel Laheru, Amy M. Thomas, Jennifer Durham, Julie M. Nauroth, Jiayun Lu, Hao Wang, Elana J. Fertig, Won Jin Ho, Nilofer S. Azad, Elizabeth M. Jaffee, Neeha Zaidi
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	Nature Portfolio 2026-02-01
سلاسل:	Nature Communications
الوصول للمادة أونلاين:	https://doi.org/10.1038/s41467-026-68324-4
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!